GlaxoSmithKline Pharmaceuticals Receives Demand Liability Order
GlaxoSmithKline Pharmaceuticals Limited announced it received a Final Order from the Assessment Circle of Income Tax (ACIT) Cir 7(1)(1) with a demand liability of 23.21 Crore Indian Rupees for the assessment year 2023-2024.The demand liability stems from a scrutiny assessment for the aforementioned assessment year. The Assessment Order was dated March 23, 2026, and received on March 24, 2026.
According to the company, it is contesting the assessment order and intends to file an appeal with the appellate authority. Currently, the company reports no impact on its financial statements.
| Sr no | Particulars | Details |
|---|---|---|
| 1 | Name of the authority | CPC |
| 2 | Nature and details of the action(s) taken, initiated or order(s) passed | Scrutiny assessment for the AY: 23-24. |
| 3 | Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority | March 24, 2026. |
Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.